Interactions : אינטראקציות

4.5       Interaction with other medicinal products and other forms of interaction
Care is required in administering Norlip to patients taking coumarin-type anti- coagulants, the action of which may be potentiated. The dosage of anti- coagulant should be reduced by up to 50% and readjusted by monitoring blood coagulation.

As Norlip improves glucose utilisation the action of antidiabetic medication, including insulin, may be potentiated. Hypoglycaemia has not been observed although increased monitoring of the glycaemic status may be warranted for a brief period after introduction of Norlip.

Should combined therapy with an ion-exchange resin be considered necessary, there should be an interval of 2 hours between the intake of the resin and Norlip as the absorption of Norlip otherwise may be impaired.

In isolated cases, a pronounced though reversible impairment of renal function (accompanied by a corresponding increase in serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant Norlip. Accordingly, renal function should be closely monitored in these patients and, in the event of relevant significant changes in laboratory parameters, Norlip, should if necessary, be discontinued.

MAO-inhibitors (with hepatotoxic potential) should not be administered together with Norlip.

Interaction between HMG CoA reductase inhibitors and fibrates may vary in nature and intensity depending on the combination of the administered drugs. A pharmacodynamic interaction between these two classes of drugs may, in some cases, also contribute to an increase in the risk of myopathy (see section 4.3 and 4.4) for specific dose recommendations of statins refer also to the SPC of the relevant product.